NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Verrica Pharmaceuticals Inc. (VRCA) Stock Analysis

Verrica Pharmaceuticals Inc. (VRCA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VRCA

$3.63

+$0.16 (+4.61%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VRCA with… →

VRCA Key Statistics

As of Oct 21, 2026
Trading
Open
$3.46
Previous Close
$3.47
Day's Range
3.44–3.64
52-Week Range
3.28–9.82
Volume
60.44K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.61
Valuation
Market Cap
$62.36M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.06
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.75
Financials (FY)
Revenue (FY)
$35.58M+370.22%
Net Income (FY)
−$17.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
−102.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.18M
1-Year Return
−10.15%
Dividend and dates
Earnings Date
November 13, 2026
Avg Volume
68.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VRCA closed at $3.63, −10.15% over 1 year.

Verrica Pharmaceuticals Inc. (VRCA) has a market capitalization of $62.36M.

In fiscal 2025, VRCA reported revenue of $35.58M.

VRCA Stock Return by Calendar Year

Verrica Pharmaceuticals Inc. (VRCA) return since Jun 2018: what $10,000 became

1 year
$10,000 $8,985
−10.15%
5 years
$10,000 $288
−97.12%
Since Jun 2018
$10,000 $207
−97.93%

If you had invested $10,000 in Verrica Pharmaceuticals Inc. (VRCA) at the close on June 15, 2018, the earliest close on record here, it would have been worth $207 at the close on October 21, 2026: −97.93% in total, −37.13% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−56.32%
2025+18.71%
2024−90.44%
2023+166.18%
2022−69.98%
2021−20.42%
2020−27.56%
2019+94.97%
2018 (partial year)−53.43%

As of October 21, 2026.

VRCA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$35.58M−$17.89M−50.3%
2024$7.57M−$76.58M−1,012.1%
2023$5.12M−$67.00M−1,307.5%
2022$9.03M−$24.49M−271.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$35.58M$32.14M−$11.94M−$17.89M−50.3%
2024$7.57M$4.83M−$65.84M−$76.58M−1,012.1%
2023$5.12M$4.38M−$63.22M−$67.00M−1,307.5%
2022$9.03M$8.31M−$21.30M−$24.49M−271.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VRCA Valuation vs Biotechnology Median

Median of 608 stocks
MetricVRCABiotechnology medianvs median
P/S ratio2.0613.300.2x the median
Profit margin−102.84%−38.31%64.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Verrica Pharmaceuticals Inc. (VRCA) is capitalised at $62.36M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 76 employees.

The most recent close on file for VRCA is $3.63, dated October 21, 2026. That is +$0.16 (+4.61%) against the previous close. Over the past 52 weeks the price has ranged from $3.28 to $9.82. The latest close sits 10.67% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $35.58M. That is +370.22% against the prior fiscal year, when revenue was $7.57M. The same year closed with a net loss of $17.89M. Profit margin runs at −102.84%. That is 64.5 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −1.75.

Across the 4 fiscal years on file, revenue moves from $9.03M in 2022 to $35.58M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.06. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.61. Daily returns over the trailing 8 years annualize to a volatility of 95.9%. The trailing one-year total return is −10.15%. Across 5 years the annualized return works out at −50.81%.

Growth & Income

The record shows no dividend for VRCA.

Across the complete calendar years on file, 2023 returned +166.18% and 2024 returned −90.44%. Of the 7 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −56.32% year to date.

Peer Comparison

Verrica Pharmaceuticals Inc. (VRCA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Verrica Pharmaceuticals Inc. VRCA $62.36M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Verrica Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Visit website →